Parcourir l'index des titres "Implications of the antiplatelet therapy gap left with discontinuation of prasugrel in Canada"
Voici les éléments 1-1 de 1
-
Implications of the antiplatelet therapy gap left with discontinuation of prasugrel in Canada
(Elsevier, 2020-12-16)Background The current Canadian Cardiovascular Society antiplatelet therapy guidelines recommend the use of ticagrelor or prasugrel over clopidogrel as first-line platelet P2Y12 receptor antagonists for treatment of moderate- to high-risk acute coronary ...